Transfusion and Apheresis Science
Volume 36, Issue 2 , Pages 149-158 , April 2007

Extracorporeal photochemotherapy (ECP) in treatment of patients with c-GVHD and CTCL

  • Zdenka Gašová

      Affiliations

    • Institute of Hematology and Blood Transfusion, Transfusion Department, U nemocnice 1, 128 20 Prague 2, Czech Republic
    • Corresponding Author InformationCorresponding author. Tel.: +420 2 2197 7342; fax: +420 2 2491 3728.
    • ,
  • Radek Spíšek

      Affiliations

    • Department of Immunology, 2nd Faculty of Medicine, Charles University, V Úvalu 84, 150 05 Prague 5, Czech Republic
    • ,
  • Ludmila Doležalová

      Affiliations

    • Institute of Hematology and Blood Transfusion, Department of Cellular Biology, U nemocnice 1, 128 20 Prague 2, Czech Republic
    • ,
  • Iuri Marinov

      Affiliations

    • Institute of Hematology and Blood Transfusion, Laboratory of Flow Cytometry, U nemocnice 1, 128 20 Prague 2, Czech Republic
    • ,
  • Antonín Vítek

      Affiliations

    • Institute of Hematology and Blood Transfusion, Department of Bone Marrow Transplantation, U nemocnice 1, 128 20 Prague 2, Czech Republic

Received 10 August 2006 ,Revised 5 January 2007 ,Accepted 6 January 2007.

References 

  1. Ratanatharathorn V, Ayash L, Lazarus HM, Fu J, Uberti JP. Chronic graft versus host disease: clinical manifestation and therapy. Bone Marrow Transpl. 2001;28:121–129
  2. Marcellus DC, Vogelsang GB. Chronic graft-versus host disease. In: Ball D, Lister J, Law P, editors. Hematopoietic stem cell therapy. Churchill Livingstone; 2000. p. 614–24 [chapter 54].
  3. Vogelsang GB, Wolff D, Altomonte V, Farmer E, Morrison WL, Corio R, et al. Treatment of chronic graft-versus-host disease with ultraviolet irradiation and psoralen (PUVA). Bone Marrow Transpl. 1996;17:1061–1067
  4. Sullivan KM, Witherspoon RP, Storb R, et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood. 1988;72(2):555–561
  5. Lazarus HM, Vogelsang GB, Rowe JM. Prevention and treatment of acute GVHD: the old and the new. A report from the Eastern Cooperative Oncology group (ECOG). Bone Marrow Transpl. 1997;19:577–600
  6. Ferrara JL. Cytokine dysregulation as a mechanism of graft-versus-host disease. Curr Opin Immunol. 1993;5:794–799
  7. Child FJ, Ratnavel R, Watkins P, et al. ECP in the treatment of chronic Graft versus Host Disease. Bone Marrow Transpl. 1999;23:881–887
  8. Bladon J, Taylor PC. ECP induces apoptosis in the lymphocytes of cutaneous T-cell lymphoma and GVHD patients. Brit J Haematol. 1999;107:707–711
  9. Van Iperen P, Beijersbergen van Henegouwen GMJ. Clinical and mechanistic aspects of photopheresis. New trends in photobiology. J Photoch Photobiol B. 1997;39:99–109
  10. Sniecinski I. Extracorporeal photochemotherapy: a scientific overview. Transfus Sci. 1994;15:429–437
  11. Schooneman F, Claise C. Treatment of GVHD by Photopheresis?. Transfus Sci. 1996;527–536
  12. Edelson RL. Transimmunization: the science catches up to the clinical success. Transfus Apher Sci. 2002;26:178–180
  13. Klosner G, Trautinger F, Knobler R, Neuner P. Treatment of peripheral blood mononuclear cells with 8-MOP Plus UV-A induces a shift in cytokine expression from a Th 1 to Th 2 response. J Invest Dermatol. 2001;116:459–462
  14. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. New Engl J Med. 1987;316:297–303
  15. Gaziev D, Galimberti M, Lucarelli G, et al. Chronic GVHD: is there an alternative to the conventional treatment?. Bone Marrow Transpl. 2000;25:689–696
  16. Kapoor N, Pellegrini AE, Copelan EA, Cunningham I, Avalos BR, Klein JL, et al. Psoralen Plus Ultraviolet A (PUVA) in the treatment of chronic graft versus host disease: preliminary experience in standard treatment resistant patients. Semin Hematol. 1992;29:108–112
  17. Owsianowski M, Gollnick H, Siegert W, et al. Successful treatment of chronic GVHD with extracorporeal photopheresis. Bone Marrow Transpl. 1994;14:845–848
  18. Owsianowski M, Garbe C, Remaker J, Orfanos CE, Gollnick H. Therapeutic experiences with extracorporeal photopheresis. Technical procedure, follow up and clinical outcome in 31 skin diseases. Hautartzt. 1996;47:114–123
  19. Andreu G, Leon A, Heshmati F, et al. Extracorporeal photochemotherapy: evaluation of two techniques and use in connective tissue disorders. Transfus Sci. 1994;15:443–454
  20. Salvaneschi L, Perroti C, Torretta L. Adverse effects associated with extracorporeal photochemotherapy. Transfusion. 2000;40:121-1
  21. Foss FM. New insights in the mechanism of action of extracorporeal photochemotherapy. Transfusion. 2006;46:6–8
  22. Foss FM, Gorgun G, Miller KB. Extracorporeal photopheresis in chronic graft-versus-host disease. Bone Marrow Transpl. 2002;29:719–725
  23. Spíšek R, Gašová Z, Bartůňková J. Maturation state of dendritic cells during the extracorporeal photopheresis and its relevance for the treatment of chronic graft versus host disease. Transfusion. 2006;46:55–65
  24. Rossetti F, Dal’Amico R, Crovetti G. Extracorporeal photochemotherapy for the treatment of graft-versus-host disease. Bone Marrow Transpl. 1996;18:175–178
  25. Girardi M, Schechner J, Glusac E, Berger C, Edelson R. Transimmunization and the evolution of extracorporeal photochemotherapy. Transfus Apher Sci. 2002;26:181–190

PII: S1473-0502(07)00020-1

doi: 10.1016/j.transci.2007.01.002

Transfusion and Apheresis Science
Volume 36, Issue 2 , Pages 149-158 , April 2007

Article Tools

* Image Usage & Resolution